Gain Therapeutics Inc reports a Return on Equity (ROE) of -151.64%.

What is GANX's dividend yield?

Gain Therapeutics Inc offers a dividend yield of 0.00%.

What is GANX's Quality Score?

Our AI rates GANX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GANX?

Our AI Timing Score for GANX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GANX belong to?

Gain Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Gain Therapeutics Inc (GANX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

GANX AI Analysis Summary

Our AI summary for GANX: Gain Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -151.64%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GANX

Gain Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 1.76

0.01 (0.57%) Day Change

Watchlist Portfolio Compare Chart

0.03

D/E

-151.6%

ROE

-113.4%

ROA

0.00%

Div Yield

GAIN THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.76 Price 0.01 (0.57%) Day Change	NEWS SCORE: 98

GANX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.76
PBV / Sector	5.33 / 44,022.72
Earning Per Share	-0.50

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	1.02 M GREAT
Average 1W Daily Value	0.74 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.24
NPM Average (%) / Sector	-26,454.73 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-113.35 / 185,260.96
ROA Average (%) / Sector	-112.54 / 36,684.70
ROA Change Average (%) / Sector	21.35 / 422,221.66 GREAT
ROE (%) / Sector	-151.64 / 243,762.23
ROE Average (%) / Sector	-161.71 / 48,758.47
ROE Change Average (%) / Sector	31.44 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:15
Symbol	GANX
Name	GAIN THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	42.65 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	74.64 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 4800 Montgomery Lane, Bethesda, MD, United States, 20814

Phone: 301 500 1556

Website: https://gaintherapeutics.com

Sector: Healthcare >> Biotechnology

Description: Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.